ReviewNuclear medicine and molecular imaging2025
Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.
Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Bridging the Gap in Theranostics: Where Do We Stand?Nuclear medicine and molecular imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is transforming the treatment landscape for prostate cancer. However, clinical data and outcomes for Asian patients remain limited and they are underrepresented in pivotal clinical trials. Although emerging retrospective series from Asia demonstrate comparable efficacy and safety profiles to Western cohorts, several points warrant attention. Asian men frequently present with aggressive, advanced-stage disease and distinct genomic profiles, characterized by lower rates of ERG fusions and TP53/PTEN mutations, and higher frequencies of FOXA1 and SPOP alterations. These genomic differences could influence PSMA expression and responsiveness to therapy. Additionally, Asian populations exhibit higher susceptibility to myelosuppression, necessitating careful patient selection and dose management. The development of region-specific radiopharmaceuticals and clinical trials, alongside systematic real-world data collection, will be essential for optimizing PSMA-targeted RLT in Asian contexts. Incorporating PSMA-based therapies earlier in disease management strategies also presents promising avenues for improving outcomes. Personalized approaches informed by ethnic-specific disease biology and clinical experience will be crucial for effectively bridging the current knowledge gaps in PSMA-targeted RLT for Asian prostate cancer patients. Clinical trial number: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.